Drugs
Conditions
News and resources
MIMS Supported Resources- Onglyza (saxagliptin) can now be prescribed as monotherapy in type II diabetes inadequately controlled by diet and exercise when metformin is contraindicated or not tolerated.
- Adults with symptomatic anaemia associated with chronic renal failure being treated with Aranesp (darbepoetin alfa) may now receive once monthly dosing in the correction phase of treatment provided they are not undergoing dialysis.
- Generic sildenafil tablets are now listed in MIMS for the treatment of erectile dysfunction.
News in brief - October 2013
Other new launches, licence changes and updates relevant to general practice.
Want news like this straight to your inbox?
Sign up for our bulletinsRead these next
Onglyza approved for triple oral therapy
Onglyza (saxagliptin) can now be used in combination...
Pancreatitis risk with DPP4 inhibitors
Acute pancreatitis is now listed as a possible adverse...
Onglyza licence extended for use in combination with insulin
Onglyza (saxagliptin) can now be prescribed in combination...
Onglyza approved for use in renal impairment
The licence for Onglyza (saxagliptin) has been extended...
New DPP4 inhibitor launched
Bristol Myers-Squibb and AstraZeneca have launched...
Aranesp dose regimens simplified
Dialysis patients with chronic renal failure receiving...
